1029720-67-9 Usage
Description
5-Bromo-3-chloroisoquinoline is a heterocyclic chemical compound and an isoquinoline derivative characterized by the presence of a bromine atom and a chlorine atom attached to a 3-position isoquinoline ring. With a molecular formula of C9H5BrClN and a molecular weight of 233.5 g/mol, this synthetic compound is utilized in various applications due to its unique chemical and physical properties.
Uses
Used in Organic Chemistry:
5-Bromo-3-chloroisoquinoline serves as a building block in the synthesis of pharmaceuticals, contributing to the development of new drugs with potential therapeutic applications. Its unique structure and reactivity facilitate the creation of diverse organic compounds, making it a valuable component in medicinal chemistry.
Used in Agrochemicals:
In the agrochemical industry, 5-bromo-3-chloroisoquinoline is utilized as a precursor for the synthesis of various agrochemicals, including pesticides and herbicides. Its chemical properties allow for the development of effective compounds that protect crops and enhance agricultural productivity.
Used in Chemical Research:
5-Bromo-3-chloroisoquinoline is employed as a valuable tool in chemical research, particularly for studying chemical reactions and mechanisms. Its distinct structure provides insights into the behavior of isoquinoline derivatives and their interactions with other molecules, furthering our understanding of organic chemistry.
Check Digit Verification of cas no
The CAS Registry Mumber 1029720-67-9 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,0,2,9,7,2 and 0 respectively; the second part has 2 digits, 6 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 1029720-67:
(9*1)+(8*0)+(7*2)+(6*9)+(5*7)+(4*2)+(3*0)+(2*6)+(1*7)=139
139 % 10 = 9
So 1029720-67-9 is a valid CAS Registry Number.
1029720-67-9Relevant articles and documents
METHODS OF USE FOR PYRIMIDINES AS FERROPORTIN INHIBITORS
-
Paragraph 1358; 1360, (2021/11/06)
The subject matter described herein is directed to ferroportin inhibitor compounds of Formula (I) and pharmaceutical salts thereof, methods of preparing the compounds, pharmaceutical compositions comprising the compounds, and methods of administering the compounds for prophylaxis and/or treatment of diseases caused by a lack of hepcidin or iron metabolism disorders, particularly iron overload states, such as thalassemia, sickle cell disease and hemochromatosis, and also kidney injuries.
